Latest updates on ACP's priorities, initiatives
ACP Spotlight offers readers a look at ACP's current top priorities and initiatives, as well as highlights from our e-newsletter, ACP Internist Weekly.
ACP's Pain Management Learning Hub releases new learning materials
In addition to the core ACP Pain Management Learning Series previously made available on the Pain Management Hub, the recently released peer-to-peer learning activities include the following:
- Addressing Bias and Disparities in Pain Management, a new episode of The DEI Shift podcast featuring Amber Brooks, MD, a board-certified anesthesiologist and comprehensive pain management physician. Dr. Brooks discusses ways to manage acute and chronic pain and how internists and members of the health care team can address disparities in vulnerable populations.
- Optimizing Pain Management in an Era of Opioid De-escalation, a six-hour on-demand course that highlights best practices in treating and managing pain.
- X-Press: The ABCs of Prescribing Buprenorphine, a video featuring Ann Garment, MD, FACP, who explains principles of buprenorphine initiation and treatment for opioid use disorder, as well as how to obtain a limited license to prescribe buprenorphine.
Each of these activities provides opportunities for ACP members to earn free CME/MOC credit and meet many state-based CME requirements. Visit the Pain Management Learning Hub to learn more. The ACP Pain Management Learning Hub and its contents are supported by an independent education grant funded by Pfizer, Inc., in partnership with Lilly USA, LLC.
ACP Hospitalist magazine relaunches with weekly online issues
ACP Hospitalist and ACP Hospitalist Weekly have merged to become a single online weekly publication covering the latest news in hospital medicine. ACP Hospitalist is a free and exclusive ACP member benefit. Each weekly issue will include:
- Top Story—Feature article or Q&A with a hospital medicine expert
- Rotating Feature—Newman's Notions, Success Story, Brief Case, or FDA Update
- Research Updates—Three to five brief articles summarizing research published in peer-reviewed journals the previous week.
ACP members can read the latest edition online or update their email subscriptions.
Call for fall 2022 Board of Governors resolutions
ACP members who are concerned about a practice or clinical issue or who have an idea to suggest might consider submitting a resolution to their Governor or chapter council.
Initiating a resolution provides ACP members an opportunity to focus attention at the ACP national level on a particular issue or topic that concerns them. All resolutions should fit within ACP's Mission and Goals and should relate to the College's Priority Themes.
Members must submit resolutions to their Governor and/or chapter council. A resolution becomes a resolution of the chapter once the chapter council approves it. The deadline for submitting new resolutions to be heard at the fall 2022 Board of Governors meeting is March 30, 2022.
ICYMI: Highlights from ACP Internist Weekly
- Melatonin use increased among U.S. adults in recent years. Use of more than the recommended daily dose of 5 mg also became more common from 2009-2010 to 2017-2018, potentially raising safety concerns, according to authors of an analysis of National Health and Nutrition Examination Survey data from 55,021 adults (mean age, 47.5 years; 52% women). The results were published as a research letter on Feb. 1 by JAMA and summarized in the Feb. 8 ACP Internist Weekly.
- Long-acting injectable cabotegravir (CAB-LA) not cost-effective for HIV pre-exposure prophylaxis (PrEP). Researchers modeled four strategies and found that over 10 years, costs would total $33.48 billion for no PrEP, $30.67 billion for generic daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF), $60.42 billion for branded emtricitabine-tenofovir alafenamide (F/TAF), and $75.84 billion for CAB-LA, inclusive of primary transmissions. The results indicate that the “incremental clinical benefits of CAB-LA would not justify a large price difference compared with F/TDF,” the authors wrote. The study should lead to future research on nuanced mixed uses of generic F/TDF and CAB-LA across populations at various levels of HIV risk over time, an accompanying editorial noted. The study and the editorial were published Feb. 1 by Annals of Internal Medicine and summarized in the Feb. 1 ACP Internist Weekly.
ACP Internist Weekly is an e-newsletter published every Tuesday and available online. Subscribe online.
